SightAtlasUK
A free UK resource

Everything you need,
in one place.

Clear, accessible information for people living with sight conditions, their family and friends, the people who support them — in fact, for anyone.

November 2026 · Reviewed monthly

Something not quite right?

💛 Why this site exists

When my daughter was diagnosed with Stargardt's, I had so many questions. I couldn't find anywhere that had everything in one place.

Find your condition

Search 38 eye conditions — get research, practical guides, benefits help & support

Type your condition then tap Search (or press Enter)

Can't find your condition? We're adding more all the time. Meanwhile, try the Fight for Sight A–Z of eye conditions (opens in a new tab), a UK charity's list.

Or search topics (benefits, daily life, support...)

Just diagnosed?

Start here.

You don't need to figure everything out today. Here are five things that actually matter in the first weeks.

Recent Updates November 2026
Site

New on Sight Atlas UK: an Eye Emergencies page (what needs 999 or A&E, what needs NHS 111 today, and what can wait) and ten new condition pages: Cataracts, Retinal Vein Occlusion, Dry Eye Disease, Uveitis, Giant Cell Arteritis, Lazy Eye and Squint, Thyroid Eye Disease, Retinal Artery Occlusion, Floaters and Flashes, and Central Serous Retinopathy.

Research

Retinitis Pigmentosa: in September 2026 Beacon Therapeutics reported that its pivotal VISTA trial of the gene therapy laru-zova met its main goal in X-linked RP. It is not available in the UK, and regulatory submissions are still to come.

Research

Stargardt: the US FDA has given tinlarebant (Belite Bio) priority review, with a decision date of 12 February 2027. A US approval would not mean it is available in the UK.

Research

Short-sightedness in children: in August 2026 NICE published draft guidance that does not recommend NHS funding in England for low-dose atropine eye drops. It is a draft, and the drops remain available privately.

Benefits

PIP & DLA rates updated April 2026 (3.8% rise): Daily Living enhanced rate £114.60/week. Mobility enhanced rate £80.00/week. Attendance Allowance higher rate £114.60/week. Carer's Allowance £86.45/week. The Timms Review of PIP published an interim report in July 2026; final recommendations are due in autumn 2026.

Research

Usher Syndrome: Ultevursen (formerly QR-421a, now owned by Laboratoires Théa) — Phase 2/3 LUNA trial recruiting since December 2024, primary completion expected December 2027.

Henshaws Knowledge Village — Featured Resource

Free video training specifically for people with sight loss — how to use an iPhone if you can't see the screen, Android accessibility, screen readers, and practical technology skills. A well-regarded free tech-training resource for people with sight loss.

Visit Henshaws Knowledge Village

Helpful YouTube Channels